• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重新审视勒克分类法:掌腱膜挛缩症的组织学分析

Re-visiting Luck's classification: a histological analysis of Dupuytren's disease.

作者信息

Lam W L, Rawlins J M, Karoo R O S, Naylor I, Sharpe D T

机构信息

Department of Plastic Surgery and Burns Research Unit, School of Biomedical Sciences, University of Bradford, Bradford, United Kingdom.

出版信息

J Hand Surg Eur Vol. 2010 May;35(4):312-7. doi: 10.1177/1753193410362848. Epub 2010 Feb 24.

DOI:10.1177/1753193410362848
PMID:20181770
Abstract

Luck (1959) described a histological staging system for Dupuytren's disease, classifying the disease into three stages. Previous biochemical and immunochemical studies have detailed the decrease in type III/I collagen ratio with disease progression. Herovici (1963) described a histological stain that produced a differential red/purple and blue colour for type I and III collagen respectively. We stained 15 specimens of Dupuytren's disease and quantified the different collagen types in each using computer analysis. We found a corresponding decrease in the amount of type III collagen as a percentage of the total collagen with disease progression: stage I range 35-49% (mean 38%); stage 2 range 21-33% (mean 27%) and stage 3 range 11-19% (mean 14%). We propose a new staging system based on the relative amount of type III collagen, where stage 1: >35%, stage 2: >20% and <35%, and stage 3: <20%.

摘要

勒克(1959年)描述了一种用于掌腱膜挛缩症的组织学分期系统,将该疾病分为三个阶段。先前的生化和免疫化学研究详细阐述了随着疾病进展,III型/I型胶原蛋白比例的降低。赫罗维奇(1963年)描述了一种组织学染色方法,该方法分别对I型和III型胶原蛋白产生不同的红/紫色和蓝色。我们对15个掌腱膜挛缩症标本进行染色,并使用计算机分析对每个标本中的不同胶原蛋白类型进行定量。我们发现随着疾病进展,III型胶原蛋白占总胶原蛋白的百分比相应降低:I期范围为35 - 49%(平均38%);II期范围为21 - 33%(平均27%),III期范围为11 - 19%(平均14%)。我们基于III型胶原蛋白的相对含量提出了一种新的分期系统,其中I期:>35%,II期:>20%且<35%,III期:<20%。

相似文献

1
Re-visiting Luck's classification: a histological analysis of Dupuytren's disease.重新审视勒克分类法:掌腱膜挛缩症的组织学分析
J Hand Surg Eur Vol. 2010 May;35(4):312-7. doi: 10.1177/1753193410362848. Epub 2010 Feb 24.
2
An insight into Dupuytren's contracture.深入了解杜普伊特伦挛缩症。
Ann R Coll Surg Engl. 1992 May;74(3):156-60; discussion 161.
3
Beta-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence.β-连环蛋白在掌腱膜挛缩症中的过表达与疾病复发无关。
Clin Orthop Relat Res. 2009 Mar;467(3):838-45. doi: 10.1007/s11999-008-0590-z. Epub 2008 Oct 29.
4
A picropolychrome staining technique applied to Dupuytren's tissue.
J Hand Surg Br. 1995 Aug;20(4):519-24. doi: 10.1016/s0266-7681(05)80167-6.
5
Androgen receptors in Dupuytren's contracture.掌腱膜挛缩症中的雄激素受体。
J Orthop Res. 2002 Jan;20(1):163-8. doi: 10.1016/S0736-0266(01)00072-9.
6
[Collagen metabolism in Dupuytren's contracture].[掌腱膜挛缩症中的胶原蛋白代谢]
Vopr Med Khim. 1978 Nov-Dec;24(6):818-21.
7
Biochemical and Histological Differences between Longitudinal and Vertical Fibres of Dupuytren's Palmar Aponeurosis and Innovative Clinical Implications.掌腱膜纵向纤维和垂直纤维的生化和组织学差异及其创新性的临床意义。
Int J Mol Sci. 2024 Jun 22;25(13):6865. doi: 10.3390/ijms25136865.
8
Epidermal growth factor receptor (EGF-R) in Dupuytren's disease.掌腱膜挛缩症中的表皮生长因子受体(EGF-R)
J Hand Surg Br. 2005 Dec;30(6):570-3. doi: 10.1016/j.jhsb.2005.06.008. Epub 2005 Aug 2.
9
[Micromorphological studies in Dupuytren's disease].
Z Orthop Ihre Grenzgeb. 1980;118(3):291-9. doi: 10.1055/s-2008-1053509.
10
Is Dupuytren's disease caused by an imbalance between proliferation and cell death?掌腱膜挛缩症是由增殖与细胞死亡之间的失衡引起的吗?
J Hand Surg Br. 1999 Oct;24(5):511-4. doi: 10.1054/jhsb.1999.0251.

引用本文的文献

1
Active synthesis of type I collagen homotrimer in Dupuytren's fibrosis is unaffected by anti-TNF-α treatment.在杜普伊特伦挛缩症纤维化中,I型胶原同三聚体的活性合成不受抗TNF-α治疗的影响。
JCI Insight. 2025 May 8;10(9). doi: 10.1172/jci.insight.175188.
2
Effect of nanoparticle-mediated delivery of SFRP4 siRNA for treating Dupuytren disease.纳米颗粒介导的SFRP4小干扰RNA递送用于治疗掌腱膜挛缩症的效果
Gene Ther. 2023 Feb;30(1-2):31-40. doi: 10.1038/s41434-022-00330-9. Epub 2022 Mar 28.
3
Echogenicity of Dupuytren's nodules is correlated to myofibroblast load and nodule hardness.
超声提示:硬纤维瘤内肌成纤维细胞负荷与硬度相关。
J Hand Surg Eur Vol. 2022 Mar;47(3):280-287. doi: 10.1177/17531934211050214. Epub 2021 Oct 7.
4
Fibroproliferative disorders and diabetes: Understanding the pathophysiologic relationship between Peyronie's disease, Dupuytren disease and diabetes.纤维增殖性疾病与糖尿病:了解 Peyronie 病、掌腱膜挛缩症和糖尿病之间的病理生理关系。
Endocrinol Diabetes Metab. 2020 Oct 31;4(2):e00195. doi: 10.1002/edm2.195. eCollection 2021 Apr.
5
Investigating the effects of Pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren's disease -derived fibroblasts.研究吡非尼酮对人掌腱膜挛缩症成纤维细胞 TGF-β1 刺激的非 SMAD 信号通路的影响。
BMC Musculoskelet Disord. 2019 Mar 30;20(1):135. doi: 10.1186/s12891-019-2486-3.
6
Association between Stenosing Tenosynovitis and Dupuytren's Contracture in the Hand.手部狭窄性腱鞘炎与掌腱膜挛缩症之间的关联
Plast Reconstr Surg Glob Open. 2019 Jan 11;7(1):e2088. doi: 10.1097/GOX.0000000000002088. eCollection 2019 Jan.
7
Cytokine Targeted Therapy for Dupuytren's Disease.
EBioMedicine. 2018 Aug;34:14-15. doi: 10.1016/j.ebiom.2018.07.016. Epub 2018 Jul 18.
8
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.抗肿瘤坏死因子疗法治疗杜普伊特伦挛缩症:一项随机剂量反应概念验证 2a 期临床试验。
EBioMedicine. 2018 Jul;33:282-288. doi: 10.1016/j.ebiom.2018.06.022. Epub 2018 Jul 6.
9
A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.一项关于掌腱膜挛缩症的全基因组关联研究揭示了另外17个与纤维化相关的变异。
Am J Hum Genet. 2017 Sep 7;101(3):417-427. doi: 10.1016/j.ajhg.2017.08.006.
10
Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症结节的疗效与安全性:一项随机对照试验
BMC Musculoskelet Disord. 2017 Aug 30;18(1):374. doi: 10.1186/s12891-017-1713-z.